Market News AIOpen the app

PMN stock news · ProMIS Neurosciences Inc.

Stories about ProMIS Neurosciences Inc. (PMN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for PMN

Follow ProMIS Neurosciences Inc. (PMN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PMN
Free on the App Store and Google Play, or on the web.
  1. Nov 12, 2026, 4:34 PM ET · Market

    ProMIS Neurosciences shared its Q3 2026 results and news about its Alzheimer's trial and new Chief Commercial Officer.

    Good for PMN

    ProMIS reported $44.1 million in cash, expected to fund operations through 2027, and kept its first-quarter 2027 trial data target. This supports its outlook, but treatment benefits remain unproven.

  2. Oct 30, 2026, 1:14 PM ET · Market

    On Friday, 12 health care stocks saw big price changes, with CareDx and Regeneron going up and Acumen dropping.

    Neutral

    ProMIS Neurosciences shares fell, but the article gives no company news or results explaining the move. The share-price change alone does not show a change in its business outlook.

  3. Oct 30, 2026, 8:14 AM ET · Market

    12 health care stocks are changing in price before the market opens, with NRX Pharmaceuticals going up and Acumen Pharmaceuticals dropping.

    Neutral

    ProMIS Neurosciences shares fell about 24% before Friday's trading. The report gives no new company news, so the share move does not change its business outlook.